S100A12 has shown very low expression in mild COVID-19 patients and no expression in severe COVID-19 patients, particularly when subgrouping differences across CD8 memory T cells and ɣδ T cells, meaning it could be a representative target in viral-induced diseases. This evidence concerns the gene CD8A and COVID-19.